drugset
drugset / Trial / NCT04046185

Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer

NCT04046185 ↗

Phase 0 Unknown 60 enrolled Shanghai First Maternity and Infant Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

We want to make a comparison of PD-1 inhibitor combined with progesterone versus progesterone alone in the treatment of early stage endometrial cancer patients who want to preserve fertility.

Timeline

Start
2019-10-01
Primary completion
2021-10-01
Completion
2022-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Progesterone Other / unclassified 160 mg Oral
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

uterine carcinoma